NCT01107535 - Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Respiratory Syncytial Virus Infection

Interventions

BIOLOGICAL

Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.

Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.

Trial Locations (4)

2

Site Reference ID/Investigator# 6059, Callao

27

Site Reference ID/Investigator# 27835, Lima

Unknown

Site Reference ID/Investigator# 27834, Arequipa

01

Site Reference ID/Investigator# 27836, Lima